Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 390Endometrial Neoplasms 223Uterine Cervical Neoplasms 217Breast Neoplasms 116Fallopian Tube Neoplasms 105Colorectal Neoplasms 91Carcinoma, Non-Small-Cell Lung 83Neoplasms 70Pancreatic Neoplasms 63Stomach Neoplasms 57Neoplasm Metastasis 54Prostatic Neoplasms 53Lung Neoplasms 49Melanoma 46Carcinoma, Ovarian Epithelial 44Triple Negative Breast Neoplasms 41Squamous Cell Carcinoma of Head and Neck 37Esophageal Neoplasms 37Carcinoma, Renal Cell 37Colonic Neoplasms 33Urinary Bladder Neoplasms 31Uterine Neoplasms 30Peritoneal Neoplasms 30Head and Neck Neoplasms 29Vulvar Neoplasms 28Carcinoma, Hepatocellular 28Small Cell Lung Carcinoma 25Carcinoma, Transitional Cell 25Uterine Cervical Dysplasia 22Sarcoma 20

Interventions

Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Platinum-resistant Recurrent Ovarian Cancer × Gynecologic × 90 days × Clear all
NCT06434610 2026-05-05

A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

Shanghai Jiaolian Drug Research and Development Co., Ltd

Phase 2 Recruiting
90 enrolled
Gynecologic

Platinum-resistant Recurrent Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡